ClinicalTrials.gg
CompletedNCT03316976Updated May 10, 2019Results posted

A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants

A Phase 1 interventional study of Dexlansoprazole in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-10.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to assess the pharmacokinetics after a single dose of dexlansoprazole 30 and 60 mg delayed-release capsules in healthy Chinese participants.

Read the detailed description

The drug being tested in this study is called Dexlansoprazole. This study will assess the pharmacokinetics, safety and tolerability of a single oral dose of Dexlansoprazole 30 mg and 60 mg delayed-release capsules in healthy participants.

The study will enroll approximately 40 participants, 20 participants in each parallel arm. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:

  • Group 1: A single oral dose of Dexlansoprazole 30 mg delayed-release capsule
  • Group 2: A single oral dose of Dexlansoprazole 60 mg delayed-release capsule

All participants will be asked to take single dose of study drug on Day 1.

This single center trial will be conducted in China. The overall time to participate in this study is approximately 40 days. Participants will be contacted by telephone or will make a final visit to the clinic 5 to 10 days after receiving their last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a healthy adult man or woman of Chinese descent.
  2. Is aged 18 to 45 years, inclusive, at the time of and study medication dose.
  3. Weighs at least 50 kilogram (kg) and has a (BMI) from 19.0 to 26.0 kilogram per square meter (kg/m\^2), inclusive at Screening Visit.

Exclusion criteria

Exclusion Criteria:

  1. Has a known to any component of the formulation of dexlansoprazole or other drug with the same mechanism of action (including lansoprazole, omeprazole, esomeprazole, rabeprazole, ilaprazole, or pantoprazole), or related compounds.
  2. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol for 48 hours prior to Check-in (Day -1) throughout the confinement and for 48 hours prior to each clinic visit and drugs throughout the study.
  3. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in (Day -1) or is unwilling to abstain from these products for the duration of the study.
  4. Has poor peripheral venous access.
  5. Has donated blood products (such as plasma), whole blood or had a significant blood loss (450 millimeter [mL]) within 56 days of Day 1.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Group 1: Dexlansoprazole 30 mg

    Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.

    Drug: Dexlansoprazole

  • Experimental
    Group 2: Dexlansoprazole 60 mg

    Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.

    Drug: Dexlansoprazole

Interventions

  • Dexlansoprazole delayed-release capsule.

    Also known as: TAK-390 Modified Release (TAK-390MR) dexlansoprazole

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose

  2. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose

  3. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole

    Time frame: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose

07

Results

Posted May 10, 2019

Participant flow

Participants took part in the study at 1 investigative site in China from 22 November 2017 to 08 February 2018.

Participant flow — Overall Study
MilestoneGroup 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mg
Started2020
Completed2020
Not completed00

Outcome measures

PrimaryCmax: Maximum Observed Plasma Concentration for Dexlansoprazole
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole
nanogram per milliliter (ng/mL)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mg
Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole732 ± 43.731756 ± 45.83
PrimaryAUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole
hour*nanogram per milliliter (h*ng/mL)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mg
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Dexlansoprazole3660 ± 61.3810198 ± 61.09
PrimaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole
Time frame:
Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose
Reported as:
Geometric mean · h*ng/mL
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole
h*ng/mLGroup 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mg
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Dexlansoprazole3701 ± 62.8310340 ± 64.20

Adverse events

Collected over Baseline up to 30 days after last dose (Day 31). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Dexlansoprazole 30 mg0/20 (0%)0/20 (0%)3/20 (15%)
Group 2: Dexlansoprazole 60 mg0/20 (0%)0/20 (0%)1/20 (5%)
Most frequent other events
Most frequent other events
EventGroup 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mg
Upper respiratory tract infectionInfections and infestations1/201/20
Alanine aminotransferase increasedInvestigations1/200/20
Blood bilirubin increasedInvestigations1/200/20
White blood cells urineInvestigations1/200/20

Baseline characteristics

The safety analysis set included all participants who were enrolled in the study and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mgTotal
Mean29.4 ± 6.7329.4 ± 5.6629.4 ± 6.14
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mgTotal
Female12719
Male81321
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mgTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mgTotal
China202040
Height
Height(centimeter)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mgTotal
Mean165.88 ± 7.688167.38 ± 7.720166.63 ± 7.642
Weight
Weight(kilogram)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mgTotal
Mean61.22 ± 8.46962.43 ± 8.54261.82 ± 8.418
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mgTotal
Mean22.17 ± 1.80822.22 ± 1.91122.20 ± 1.836
Smoking Classification
Smoking Classification(Participants)Group 1: Dexlansoprazole 30 mgGroup 2: Dexlansoprazole 60 mgTotal
Never smoked151732
Ex-Smoker538

3 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Phase I Clinical Trial Department
    Beijing, Beijing 100005, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Feb 2018, 2 months.

Results were first posted in May 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2017
First posted
Oct 23, 2017
StartActual
Nov 22, 2017
Primary completionActual
Feb 8, 2018
CompletionActual
Feb 8, 2018
Results first posted
May 10, 2019
Last update
May 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03316976
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 23, 2017
Start date
Nov 22, 2017
Primary completion
Feb 8, 2018
Completion
Feb 8, 2018
Results posted
May 10, 2019
Last update
May 10, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexlansoprazole

Start the discussion